Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
The Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial of patients at high risk of vascular disease found that adding extended-release niacin-laropiprant to intensive statin-based LDL-lowering therapy had no benefit on cardiovascular outcomes. However, the trial also identified previously unrecognized serious adverse effects (including new-onset diabetes, bleeding, and infection). Our objective was to exp...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Accepted manuscript, pdf, 224.9KB)
- Publisher copy:
- Copyright holder:
- Haynes, R et al.
- Copyright date:
- Rights statement:
- © 2019 Haynes, R et al. Published by Elsevier Inc.
- This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.clinthera.2019.06.012
If you are the owner of this record, you can report an update to it here: Report update to this record